Browse > Article
http://dx.doi.org/10.7732/kjpr.2014.27.6.593

Anti-osteoporotic Effects of Unripe Fructus of Rubus coreanus Miquel in Osteoblastic and Osteoclastic Cells  

Kim, Hyo Jin (Department of Herbal Medicine Resource, Kangwon National University)
Sim, Dong-Soo (Department of Herbal Medicine Resource, Kangwon National University)
Sohn, Eun-Hwa (Department of Herbal Medicine Resource, Kangwon National University)
Publication Information
Korean Journal of Plant Resources / v.27, no.6, 2014 , pp. 593-600 More about this Journal
Abstract
Osteoporosis is a progressive bone disease characterized by low bone mass which is caused by disturbance in the balance between the activities of osteoblasts and osteoclasts. Postmenopausal osteoporosis is one of the most common disorders in women after menopause, which is linked to an estrogen deficiency and characterized by an excessive loss of trabecular bone. Rubus coreanus has been used for their various pharmacological properties in Asia as a traditional medicine. To investigate the effect of unripe fruits of R. coreanus 30% ethanol extract (RCE) on osteoblast-like cells (MG63) differentiation, we examined the effects of RCE on in vitro osteoblastic differentiation markers, alkaline phosphatase (ALP) activity and receptor activator of nuclear factor ${\kappa}$-B ligand (RANKL) and osteoprotegerin (OPG) expression. The high concentration (50 and $100{\mu}g/mL$) of RCE markedly increased ALP activity, whereas decreased the RANKL/OPG. We also investigated the effect of RCE on M-CSF plus RANKL-induced differentiation of pre-osteoclast cells (RAW 264.7). RCE treatment remarkably inhibited M-CSF/RANKL-induced formation of osteoclast-like multinuclear cells from RAW 264.7 cells. Moreover, the inhibitory effect of RCE was reduced by selective estrogen receptor-${\alpha}$ antagonist. Our research suggests that suggested that unripe fruits of R. coreanus may act beneficial effects on bone mass by regulating both osteoblast and osteoclast.
Keywords
Osteoblast; Osteoclast; Osteoporosis; RANKL; Rubus coreanus;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Miksicek, R.J. 1994. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J. Steroid Biochem. Mol. Biol. 49:153-160.   DOI   ScienceOn
2 Oliveira, C.A., R. Nie, K. Carnes, L.R. Franca, G.S. Prins, P.T. Saunders and R.A. Hess. 2003. The antiestrogen ICI 182,780 decreases the expression of estrogenreceptor-alpha but has no effect on estrogenreceptor-beta and androgen receptor in rat efferent ductules. Reprod. Biol. Endocrinol. 1:75.   DOI   ScienceOn
3 Park, J.H., S.M. Oh, S.S. Lim, Y.S. Lee, H.K. Shin, Y.S. Oh, N.H. Choe, J.H. Park and J.K. Kim. 2006. Induction of heme oxygenase-1 mediates the anti-inflammatory effects of the ethanol extract of Rubus coreanus in murine macrophages. Biochem. Biophys. Res. Commun. 351:146-152.   DOI   ScienceOn
4 Simonet, W.S., D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Luthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee and W.J. Boyle. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.   DOI   ScienceOn
5 Khosla, S. 2001. Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055.   DOI
6 Kostenuik, P.J. and V. Shalhoub. 2001. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des. 7:613-635.   DOI   ScienceOn
7 Koo, H.J., E.H. Sohn, Y.J. Kim, S.A. Jang, S. Namkoong and S.C. Kang. 2014a. Effect of the combinatory mixture of Rubus coreanus Miquel and Astragalus membranaceus Bunge extracts on ovariectomy-induced osteoporosis in mice and anti-RANK signaling effect. J. Ethnopharmacol. 151:951-959.   DOI
8 Koo, H.J., S.C. Kang, S.A. Jang, J.E. Kwon, E. Sohn and E.H. Sohn. 2014b. Effects of protocatechuic acid derived from Rubus coreanus on the lipid metabolism in high cholesterol diet-induced mice. Korean J. Plant Res. 27:271-278.   과학기술학회마을   DOI
9 Lee, J.E., S.M. Cho, E. Park, S.M. Lee, Y. Kim, J.H. Auh, H.K. Choi, S. Lim, S.C. Lee and J.H. Kim. 2014. Anti-inflammatory effects of Rubus coreanus Miquel through inhibition of NF-${\kappa}B$ and MAP Kinase. Nutr. Res. Pract. 8:501-508.   과학기술학회마을   DOI
10 Lee, K.H. and E.M. Choi. 2006. Rubus coreanus Miq. extract promotes osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. Am. J. Chin. Med. 34:643-654.   DOI   ScienceOn
11 Marsden, J. 2002. The menopause, hormone replacement therapy and breast cancer. J. Steroid Biochem. Mol. Biol. 83:123-132.   DOI
12 McNamara, L.M. 2010. Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J. R. Soc. Interface 7:353-372.   DOI
13 Riggs, B.L., S. Khosla and L.J. Melton III. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302.   DOI
14 Kansra, S., S. Chen, M.L. Bangaru, L. Sneade, J.A. Dunckley and N. Ben-Jonathan. 2010. Selective estrogen receptor down-regulator and selective estrogen receptor modulators differentially regulate lactotroph proliferation. PLoS One 5:e10060.   DOI
15 Jang, J.H., J.H. Kim, B.H. Ahn and J.S. Lee. 2011. Physiological functionalities of Vitis hybrid (Sheridan)-Rubus coreanus red wine made by Saccharomyces cerevisiae. Mycobiology 39:109-112.   과학기술학회마을   DOI
16 Jung, K.A., D. Han, E.K. Kwon, C.H. Lee and Y.E. Kim. 2007. Antifatigue effect of Rubus coreanus Miquel extract in mice. J. Med. Food 10:689-693.   DOI   ScienceOn
17 Kansra, S., S. Yamagata, L. Sneade, L. Foster and N. Ben Jonathan. 2005. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol. Cell. Endocrinol. 239:27-36.   DOI
18 Kelly, P.J. 1996. Is osteoporosis a genetically determined disease? Br. J. Obstet. Gynaecol. 103:20-26.
19 Kim, S., C.K. Kim, K.S. Lee, J.H. Kim, H. Hwang, D. Jeoung, J. Choe, M.H. Won, H. Lee, K.S. Ha, Y.G. Kwon and Y.M. Kim. 2013. Aqueous extract of unripe Rubus coreanus fruit attenuates atherosclerosis by improving blood lipid profile and inhibiting NF-${\kappa}B$ activation via phase II gene expression. J. Ethnopharmacol. 146:515-524.   DOI   ScienceOn
20 Karsenty, G. 2003. The complexities of skeletal biology. Nature 423:316-318.   DOI   ScienceOn
21 Kearns, A.E., S. Khosla and P.J. Kostenuik. 2008. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29:155-192.   DOI
22 Choi, C., H. Lee, H. Lim, S. Park, J. Lee and S. Do. 2012. Effect of Rubus coreanus extracts on diabetic osteoporosis by simultaneous regulation of osteoblasts and osteoclasts. Menopause 19:1043-1051.   DOI
23 Koo, H.J., S.C. Kang and E.H. Sohn. 2013. The optimal combination of the mixture of unripe Rubus coreanus and Astragalus membranaceus in the activation and differentiation of osteoblastic cells. Korean J. Plant Res. 26:658-662 (in Korean).   과학기술학회마을   DOI
24 Fraser, L.A., K.N. Vogt, J.D. Adachi and L. Thabane. 2011. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther. Clin. Risk Manag. 7:157-166.
25 Aubin, J.E. and J.T. Triffitt. 2002. Mesenchymal stem cells and osteoblast differentiation: In Bilezikian, J.P., L.G. Raisz and G.A. Rodan (eds.), Principles of Bone Biology, 2nd edn. Academic Press, San Diego, USA. pp. 59-81.
26 Do, S.H., J.W. Lee, W.I. Jeong, J.Y. Chung, S.J. Park, I.H. Hong, S.K. Jeon, I.S. Lee and K.S. Jeong. 2008. Boneprotecting effect of Rubus coreanus by dual regulation of osteoblasts and osteoclasts. Menopause 15:676-683.   DOI   ScienceOn
27 Geller, S.E. and F. Kronenberg. 2003. Toward optimal health: the experts discuss the use of botanicals by women. J. Womens Health (Larchmt) 12:847-852.   DOI
28 Hamdy, N.A. 2007. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr. Opin. Investig. Drugs 8:299-303.
29 Hotokezaka, H., E. Sakai, N. Ohara, Y. Hotokezaka, C. Gonzales, K. Matsuo, Y. Fujimura, N. Yoshida and K. Nakayama. 2007. Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J. Cell. Biochem. 101:122-134.   DOI
30 Horwood, N.J., J. Elliott, T.J. Martin and M.T. Gillespie. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743-4746.   DOI
31 Yang, H.M., S.M. Oh, S.S. Lim, H.K. Shin, Y.S. Oh and J.K. Kim. 2008. Antiinflammatory activities of Rubus coreanus depend on the degree of fruit ripening. Phytother. Res. 22:102-107.   DOI   ScienceOn
32 Thomas, G.P., S.U. Baker, J.A. Eisman and E.M. Gardiner. 2001. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170:451-460.   DOI   ScienceOn
33 Udagawa, N., N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, M.T. Gillespie, T.J. Martin, K. Higashio and T. Suda. 2000. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484.   DOI
34 Wensel, T.M., M.M. Iranikhah and T.W. Wilborn. 2011. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Pharmacotherapy 31:510-523.   DOI